IP Library › Granted Patent US 10,961,198
Granted Patent B2
US 10,961,198 · App. 16/494,264 · Granted Mar 30, 2021

Farnesoid X receptor agonists and uses thereof

Inventors: Nicholas D. Smith (San Diego, CA); Steven P. Govek (San Diego, CA); Johnny Y. Nagasawa (San Diego, CA)
Assignee: METACRINE, INC.
C07D231/12A61K9/0014A61K9/0029A61K9/0053A61K9/06A61K9/2054A61K9/4866A61P1/00A61P1/16C07D401/04C07D401/14C07D403/12C07D405/12C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,198
App. No.
16/494,264
Granted
Mar 30, 2021
Kind
B2
Abstract

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Claims (7)

1. A method of treating fatty liver in a mammal, comprising administering to the mammal with fatty liver a compound that has the following structure:

or a pharmaceutically acceptable salt or solvate thereof.

2. A method of treating a disease or condition in a mammal, comprising administering to the mammal in need thereof a compound that has the following structure:

or a pharmaceutically acceptable salt or solvate thereof;

wherein the disease or condition is primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), inflammatory bowel disease, irritable bowel syndrome, or bile acid diarrhea.

3. The method of claim 2 , further comprising administering at least one additional therapeutic agent to the mammal.

4. The method of claim 1 , further comprising administering at least one additional therapeutic agent to the mammal.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2025
From: ORGANOVO, INC.
To: ELI LILLY AND COMPANY
Reel/Frame 070892/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: METACRINE, INC.
To: ORGANOVO, INC.
Reel/Frame 063354/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2019
From: SMITH, NICHOLAS D.; GOVEK, STEVEN P.; NAGASAWA, JOHNNY Y.
To: METACRINE, INC.
Reel/Frame 050399/0667 →
Continuity (2)
Provisional Application 62471517 · Mar 15, 2017
Related Publication 20200131134A1 · Apr 30, 2020